Swapping two chemotherapy cycles for blinatumomab lifted four-year event-free survival from 70% to 83% in high-risk childhood leukaemia

Design

randomised, 1:1, open-label trial with planned interim analysis (AIEOP-BFM ALL 2017)

Population

709 children with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia, randomised after consolidation

Primary outcome

event-free survival (resistance to protocol treatment, relapse, second cancer or death)

Effect

4-year event-free survival 83.0% (95% CI 77.4-87.4) vs 70.3% (95% CI 63.8-75.9); HR 0.51 (95% CI 0.35-0.73); treatment-related infection 23.9% vs 69.4%

In the AIEOP-BFM ALL 2017 trial, 709 children with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia were randomised after consolidation to two cycles of blinatumomab or two cycles of conventional chemotherapy. At a planned interim analysis with median follow-up of 2.9 years, estimated four-year event-free survival was 83.0% with blinatumomab and 70.3% with chemotherapy.

The toxicity comparison is as striking as the efficacy one and runs in the same direction. Treatment-related infection occurred in 23.9% of the blinatumomab group against 69.4% of the chemotherapy group. Life-threatening adverse events were 0.5% versus 4.7%. This is unusual: a substitution that both works better and harms less, rather than trading one against the other.

Blinatumomab is not free of specific toxicity. Neurotoxic events were more common — 12.0% versus 3.2% — and cytokine release syndrome of grade 2 or higher occurred in 1.1%. Both are manageable in centres familiar with the agent and both need naming when a family is consented.

For a clinician outside haemato-oncology the relevance is in what families will now ask. Blinatumomab requires continuous infusion over each cycle and is expensive; access in India is limited and uneven. A parent who has read this result deserves an honest answer about whether it is obtainable where they are being treated, rather than reassurance that their child is getting the same thing.

• Expect questions from families of children with B-cell ALL; the result is large enough to reach general readership
• Refer the availability question to the treating centre rather than answering it generically — access varies widely
• Name neurotoxicity and cytokine release syndrome as the specific risks, since the general toxicity comparison favours blinatumomab
• Note that this replaced two cycles after consolidation, not the whole protocol
• Interim analyses stop early on efficacy; the four-year figures are estimates from 2.9 years of median follow-up

The statistics, in plain English

The hazard ratio of 0.51 with a 95% confidence interval of 0.35 to 0.73 means events occurred at about half the rate in the blinatumomab arm, and the interval is comfortably below 1.0. But this is a planned interim analysis at 2.9 years median follow-up reporting a four-year estimate, so the 83.0% and 70.3% figures are extrapolations from Kaplan-Meier curves rather than four years of observed data, and their confidence intervals — 77.4 to 87.4 and 63.8 to 75.9 — reflect that. Trials stopped at interim analysis for efficacy tend to overstate the effect somewhat; the direction here is not in doubt, the exact magnitude is.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.